{
  "id": "61f5847b882a024a10000008",
  "type": "factoid",
  "question": "Which receptor is targeted by Spesolimab?",
  "ideal_answer": "Spesolimab is a novel anti-interleukin-36 receptor antibody.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33919434",
    "http://www.ncbi.nlm.nih.gov/pubmed/34626330",
    "http://www.ncbi.nlm.nih.gov/pubmed/34678325",
    "http://www.ncbi.nlm.nih.gov/pubmed/33661508",
    "http://www.ncbi.nlm.nih.gov/pubmed/33785490",
    "http://www.ncbi.nlm.nih.gov/pubmed/34085329",
    "http://www.ncbi.nlm.nih.gov/pubmed/32884319"
  ],
  "snippets": [
    {
      "text": "A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP flare.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33785490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The objectives of this study were to evaluate the safety and efficacy of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients with PPP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33661508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Directing treatment at neutrophil recruitment and activation by targeting IL-36 with spesolimab fits well in the pathogenic concept of HS and clinical phase II trial results are pending.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34085329",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two IL-36R blocking antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33919434",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP flares.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34678325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, specific inhibitors of the IL-36 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626330",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33661508",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP flares.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34678325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, blockage of the IL-36 pathway has become a new treatment target in PPP, and three studies are currently evaluating the use of monoclonal antibodies that block the IL-36 receptor in PPP: ANB019 and spesolimab (BI 655130).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32884319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, specific inhibitors of the IL-36 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626330",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "h PPP. The objectives of this study were to evaluate the safety and efficacy of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients wit",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33661508",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "6 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP. The emerging drugs for pustular psoriasis ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34626330",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ares. A prior Phase I proof-of-concept study showed rapid improvements in skin and pustule clearance with a single intravenous dose of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients presenting with an acute GPP f",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33785490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "IL-36 pathway has become a new treatment target in PPP, and three studies are currently evaluating the use of monoclonal antibodies that block the IL-36 receptor in PPP: ANB019 and spesolimab (BI 655130). In this review, we explore ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32884319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ent at neutrophil recruitment and activation by targeting IL-36 with spesolimab fits well in the pathogenic concept of HS and clinical phase II trial results are pending. In contrast to",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34085329",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "is (GPP). In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34678325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "asis (GPP). In a proof-of-concept clinical trial, treatment with spesolimab, an anti-IL-36 receptor antibody, resulted in rapid skin and pustular clearance in patients presenting with GPP flares.OBJECTIVE: We sought to compare the molecular profiles of lesional and nonlesional skin from patients with GPP or palmoplantar pustulosis (PPP) with skin from healthy volunteers, and to investigate the molecular changes after spesolimab treatment in the skin and blood of patients with GPP flares.METHODS: Pre- and post-treatment skin and blood samples were collected from patients with GPP who participated in a si",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34678325",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "interleukin-36"
}